Mangoceuticals shares are trading higher after the company announced the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone in an Oral Dissolvable Tablet for the treatment of low testosterone and male hormone imbalances.
Portfolio Pulse from Benzinga Newsdesk
Mangoceuticals shares are trading higher following the announcement of new proprietary formulations for treating low testosterone and male hormone imbalances.
June 04, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mangoceuticals shares are trading higher after the company announced the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone, and Dehydroepiandrosterone in an Oral Dissolvable Tablet for the treatment of low testosterone and male hormone imbalances.
The announcement of new proprietary formulations for treating low testosterone and male hormone imbalances is a significant development for Mangoceuticals. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100